Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Topical Minocycline for Cutaneous Allergic Responses
NCT04202263Phase 2
Key facts
- Status
- Unknown
- Start
- Sep 2019
- Primary completion
- Sep 2023
- Countries
- 1
- Sponsor
- SUNY Downstate Health Sciences University
- Modality
- Transdermal Patches, Small Molecules
- Drugs
- zilxi
- Conditions
- pruritusHypersensitivity
01
Overview
Phase 2, randomised, double-blind trial of zilxi in pruritus and Hypersensitivity (2 arms), sponsored by SUNY Downstate Health Sciences University. Primary endpoint: Change in mean diameter of treatment induced effect on wheal size at 24 hours. Status: unknown.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Placebo
Placebo cream applied to one skin test site
Minocycline Arm
Minocycline cream (1%, 2%, or 3%) applied to skin test sites
03
Endpoints
Primary
Change in mean diameter of treatment induced effect on wheal size
Secondary
Change in itch scores by minocycline 1%, 2%, and 3% vs. placebo
Beyond the preview
Go deeper on NCT04202263.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202263.